Get the Stockscreener App
23.93
7.39%
-1.91
After Hours:
24.18
0.25
+1.04%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $23.93, with a volume of 1.89M.
It is down -7.39% in the last 24 hours and down -11.63% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
See More
Previous Close:
$25.84
Open:
$25.54
24h Volume:
1.89M
Relative Volume:
0.87
Market Cap:
$1.15B
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-10.93
EPS:
-2.19
Net Cash Flow:
$-82.44M
1W Performance:
-9.77%
1M Performance:
-11.63%
6M Performance:
+8.53%
1Y Performance:
+5.42%
1-Day Range:
$23.45
$25.70
1-Week Range:
$23.45
$26.70
52-Week Range:
$8.79
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Cassava Sciences (NASDAQ:SAVA) Trading Down 5.8%Should You Sell? - MarketBeat
Unpacking the Latest Options Trading Trends in Cassava Sciences - Benzinga
Analysts Believe Cassava Sciences Now Has 300% Upside From Here - MSN
Cassava Sciences (SAVA) Scheduled to Post Earnings on Thursday - MarketBeat
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 - GlobeNewswire
International Assets Investment Management LLC Makes New Investment in Cassava Sciences, Inc. (NASDAQ:SAVA) - MarketBeat
Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value - Yahoo Finance
Long Term Trading Analysis for (SAVA) - Stock Traders Daily
Cassava Sciences Inc (SAVA-Q) QuotePress Release - The Globe and Mail
HC Wainwright & Co. Upgrades Cassava Sciences (SAVA) - MSN
Cassava Sciences Options Trading: A Deep Dive into Market Sentiment - Benzinga
Institutions profited after Cassava Sciences, Inc.'s (NASDAQ:SAVA) market cap rose US$72m last week but individual investors profited the most - Simply Wall St
(SAVA) Proactive Strategies - Stock Traders Daily
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge - Insider Monkey
Cassava Sciences (NASDAQ:SAVA) Trading 5.1% HigherWhat's Next? - MarketBeat
HC Wainwright Comments on Cassava Sciences, Inc.'s FY2025 Earnings (NASDAQ:SAVA) - MarketBeat
After Cassava Fraud Indictment, Questioning the Ethics of Simufilam Trial - Being Patient
Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement - Yahoo Finance
Cassava Sciences: Phase III trials storm ahead amid controversy - Yahoo Finance
(SAVA) Long Term Investment Analysis - Stock Traders Daily
Cassava Sciences Stock Jumps After CEO’s Update On Alzheimer’s Drug Trial: Retail Sentiment Wavers - Barchart
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August - Benzinga
Cassava Sciences (NASDAQ:SAVA) Shares Gap UpTime to Buy? - MarketBeat
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday? - Benzinga
Cassava Sciences earns rare buy as H.C. Wainwright upgrades post settlement - MSN
Why Is Bio-Path Holdings Stock Soaring On Tuesday?Cassava Sciences (NASDAQ:SAVA) - Benzinga
Cassava Sciences stock upgraded at H.C. Wainwright (NASDAQ:SAVA) - Seeking Alpha
Cassava Sciences (NASDAQ:SAVA) Lifted to Buy at HC Wainwright - MarketBeat
Cassava agrees to $40M settlement over misleading Alzheimer’s clinical trial statements - Top Class Actions
An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped? - BioPharma Dive
Cassava's Alzheimer's Therapy: A Confidence Bet - Seeking Alpha
SEC brings securities fraud charges against Cassava Sciences - JD Supra
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session - MSN
SAVA Stock Down On Settling Misleading Alzheimer's Study Data Claims - Barchart
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims - Zacks Investment Research
Company News for Sep 30, 2024 - Yahoo Finance
SEC charges Cassava over 'misleading' Alzheimer's claims - pharmaphorum
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, and More - MSN
Cassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA) - MarketBeat
Why Cassava Sciences Stock Dived by Almost 11% Today - MSN
(SAVA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Stocks to Watch Friday: Bristol-Myers Squibb, Costco, Cassava Sciences, EchoStar - The Wall Street Journal
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement - MSN
Bristol Myers, Costco, EchoStar, DJT, Wynn, HP Inc., and More Stock Movers - Barron's
Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims - Yahoo Finance
Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more - CNBC
Cassava Sciences (NASDAQ:SAVA) Shares Gap Down to $31.87 - MarketBeat
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):